Mr. Robert Thast reports

IZOTROPIC ENGAGES MARKET AWARENESS CONSULTANT

Izotropic Corp. has engaged Douglas McKay and Associates (DMA) to assist the company with its communications and financing initiatives.

Subject to necessary approvals from the Canadian Securities Exchange, DMA has been engaged under the following agreement terms:

Agreement length:

• Six months, with an option to extend.

Remuneration:

• Monthly fee of $7,000 that will be deferred until the company completes its next financing (currently undertaking);
• 400,000 stock options at an exercise price of 27.5 cents for a two-year term; the stock options will vest according to the following schedule: 50 per cent of the stock options will vest on Sept. 27, 2023, and 50 per cent of the stock options on Dec. 27, 2023;
• 300,000 restricted share units; the restricted share units will vest according to the following schedule: 100,000 shares on Aug. 27, 2023, 100,000 shares on Oct. 27, 2023, and 100,000 shares on Dec. 27, 2023.

Izotropic had previously engaged DMA in 2020 as part of its awareness building initiatives. DMA was effective at attracting many new shareholders and assisted the company by introducing several medical professionals and other individuals who participated into two separate financings completed in 2020. The company looks forward to working with DMA again as it moves forward on its recently announced modified market approval pathway and strategy for Food and Drug Administration market clearance in the United States.

We seek Safe Harbor.